Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO), announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The move follows Siegfried's previously announced decision to combine the Chief Operating Officer roles for Drug Substances and Drug Products into a single position, aligning with the company's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Eduardo Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
With his strong track record in integrated operations, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. Siegfried operates 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China, and in 2025 achieved sales of CHF 1,327.8 million with over 3,800 employees.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, stated: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He has extensive international leadership experience, having lived and worked across Europe and Latin America. His appointment underscores Siegfried's commitment to integrated operations and its strategy to offer comprehensive CDMO services from drug substances to drug products.
This leadership change is significant for the pharmaceutical industry as it reflects the growing trend among CDMOs to streamline operations and provide seamless end-to-end solutions. By consolidating the COO roles, Siegfried aims to enhance collaboration between its Drug Substances and Drug Products divisions, potentially leading to faster development timelines and improved supply chain reliability for its clients. For the industry, this move signals that integrated operational leadership is becoming a key competitive advantage in the CDMO space.
Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN). More information about the company can be found at https://www.siegfried.ch.
